# US 2013/0252937 A1 · New indanyloxydihydrobenzofuranylacetic acids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252937 A1
- Document ID: US20130252937A1
- Status: Published application
- Kind: A1
- Application number: 13/803,237
- Filed: 2013-03-14
- Published: 2013-09-26
- Earliest claimed: 2012-03-26
- Assignees: Boehringer Ingelheim International GmbH
- Inventors: Matthias ECKHARDT; Sara FRATTINI; Dieter HAMPRECHT; Frank HIMMELSBACH; Elke LANGKOPF; Iain LINGARD; Stefan PETERS; Holger WAGNER
- Web page: https://patentgrep.com/patent/US20130252937A1

## CPC

- C07D 405/12: linked by a chain containing hetero atoms as chain links
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/351: not condensed with another ring
- A61K 31/382: having six-membered rings, e.g. thioxanthenes (thiothixene A61K31/496)
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/4245: Oxadiazoles
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/443: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/497: containing further heterocyclic rings
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- C07D 307/80: Radicals substituted by oxygen atoms
- C07D 405/14: containing three or more hetero rings
- C07D 407/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds of general formula I, wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

## Claims

### Claim 1

A compound of formula I
wherein
R1 is selected from the group consisting of a phenyl ring, a tetrazolyl ring, and a 5- or 6-membered heteroaromatic ring which contains 1, 2, or 3 heteroatoms independently of each other selected from ═N—, —NH—, —O— and —S—;
wherein optionally a second ring is annulated to said phenyl or heteroaromatic ring,
wherein said second ring is 5- or 6-membered, partially unsaturated or aromatic and may contain 1, 2, or 3 heteroatoms independently of each other selected from ═N—, —NH—, —O— and —S— with the proviso that only up to two of the heteroatoms are O and S and no O—O, S—S, and S—O bond is formed, and
wherein in said second ring independently of the presence of heteroatoms 1 or 2 CH2 groups may be replaced by —C(═O)—, —S(═O)— or —S(═O)2—, and
wherein said phenyl ring, tetrazolyl ring, heteroaromatic ring, annulated phenyl ring, and annulated heteroaromatic ring are substituted with one group R3; and
wherein each of the phenyl ring, tetrazolyl ring, heteroaromatic ring, annulated phenyl ring, and annulated heteroaromatic ring is optionally additionally substituted with 1 to 4 groups independently selected from R4; and
wherein in said heteroaromatic ring and/or said second ring the H-atom in one or more NH groups, if present, is replaced by RN or R3;
R2 is selected from the group R2-G1 consisting of F, Cl, Br, I, C1-4-alkyl, C3-6-cycloalkyl, NC—, H2N—C(═O)—, C1-4-alkyl-NRN—C(═O)—, HO—O(═O)—, C1-4-alkyl-O—C(═O)—, C1-4-alkyloxy, and C1-4-alkyl-S(═O)2—,
wherein any alkyl and cycloalkyl group or sub-group within the groups mentioned is optionally substituted with one or more F atoms, and wherein multiple R2 may be identical or different, if m is 2 or 3;
R3 is selected from the group consisting of
C1-6-alkyl, C2-6-alkenyl, C2-6-alkinyl, C3-6-cycloalkyl-, C1-4-alkyl-NH—, (C1-4-alkyl)2N—, C1-6-alkyl-O—, C3-6-cycloalkyl-O—, C1-4-alkyl-S—, C1-4-alkyl-S(═O)—, and C1-4-alkyl-S(═O)2,
wherein each alkyl and cycloalkyl group and each alkyl and cycloalkyl sub-group within the groups mentioned is substituted with 1 to 3 groups independently selected from R5 and optionally substituted with 1 or more F atoms;
or from C1-4-alkyl-C(═O)—, heterocyclyl-C(═O)—, HNRN—C(═O)—, C1-4-alkyl-NRN—C(═O)—, C3-6-cycloalkyl-NRN—C(═O)—, heterocyclyl-NRN—C(═O)—, phenyl-NRN—C(═O)—, heteroaryl-NRN—C(═O)—, HO2C—, C1-4-alkyl-O—C(═O)—, C3-6-cycloalkyl-O—C(═O)—, heterocyclyl-O—C(═O)—, —NHRN, C1-4-alkyl-C(═O)NRN—, C3-6-cycloalkyl-C(═O)NRN—, heterocyclyl-C(═O)NRN—, phenyl-C(═O)NRN—, heteroaryl-C(═O)NRN—, C1-4-alkyl-S(═O)2NRN—, C3-6-cycloalkyl-S(═O)2NRN—, heterocyclyl-S(═O)2NRN—, phenyl-S(═O)2NRN—, heteroaryl-S(═O)2NRN—, heterocyclyl-O—, phenyl-O—, heteroaryl-O—, C3-6-cycloalkyl-S—, heterocyclyl-S—, phenyl-S—, heteroaryl-S—, C3-6-cycloalkyl-S(═O)—, heterocyclyl-S(═O)—, phenyl-S(═O)—, heteroaryl-S(═O)—, C3-6-cycloalkyl-S(═O)2—, heterocyclyl-S(═O)2—, phenyl-S(═O)2—, heteroaryl-S(═O)2—, HNRN—S(═O)2—, C1-4-alkyl-NRN—S(═O)2—, heterocyclyl, phenyl, and heteroaryl,
wherein each alkyl, cycloalkyl, and heterocyclyl group or sub-group within the groups mentioned is optionally substituted with 1 to 3 groups independently selected from R5 and optionally substituted with 1 or more F atoms; and
wherein each phenyl and heteroaryl group is optionally substituted with 1 to 5 substituents independently selected from R6;
wherein heterocyclyl is selected from
a cyclobutyl group wherein 1 CH2 group is replaced by —NH— or —O—,
a saturated or partially unsaturated C5-7-cycloalkyl group wherein 1 CH2 group is replaced by —C(═O)—, —NH—, —O—, —S(═O)— or —S(═O)2— and/or 1 CH group by N;
a saturated or partially unsaturated C5-7-cycloalkyl group wherein 1 CH2 group is replaced by —NH— or —O—, a second CH2 group is replaced by —NH—, —C(═O)—, —S(═O)— or —S(═O)2— and/or 1 CH group is replaced by N; and
a saturated or partially unsaturated C5-7-cycloalkyl group wherein 2 CH2 groups are replaced by —NH— or 1 CH2 group by —NH— and the other by —O— and a third CH2 group is replaced by —O(═O)—, —S(═O)— or —S(═O)2— and/or 1 CH group by N;
wherein heteroaryl is selected from
a tetrazolyl ring, and a 5- or 6-membered heteroaromatic ring which contains 1, 2, or 3 heteroatoms independently of each other selected from ═N—, —NH—, —O—, and —S—, wherein in heteroaromatic groups containing a —HC═N— unit this group is optionally replaced by —NH—C(═O)—;
wherein in heteroaryl and heterocyclyl rings with one or more NH groups each of them is replaced by NRN or NR5,
with the proviso that R3 in total cannot be C1-4-alkyl-, C1-4-alkyl-O—C1-4-alkyl, HO—C1-4-alkyl, C3-4-alkenyl, C3-4-alkenyl, H2N—, (C1-4-alkyl)2N—, C1-4-alkyl-O—, C1-4-alkyl-S—, C1-4-alkyl-S(═O)—, and C1-4-alkyl-S(═O)2—;
R4 is selected from the group consisting of F, Cl, Br, I, CN, —OH, C1-4-alkyl, C3-6-cycloalkyl, HO—C1-4-alkyl, C1-4-alkyl-O—C1-4-alkyl, —NRNH, C1-4-alkyl-NRN—, C1-4-alkyl-O—, C3-6-cycloalkyl-O—, C1-4-alkyl-O—C1-4-alkyl-O—, C1-4-alkyl-S—, C1-4-alkyl-S(═O)—, and C1-4-alkyl-S(═O)2—,
wherein any alkyl and cycloalkyl group or sub-group within the groups mentioned is optionally substituted with 1 or more F atoms;
R5 is selected from the group consisting of Cl, Br, I, C1-4-alkyl-, CN, C3-6-cycloalkyl-, heterocyclyl-O(═O)—, H2N—C(═O)—, C1-4-alkyl-NRN—C(═O)—, C3-6-cycloalkyl-NRN—C(═O)—, heterocyclyl-NRN—C(═O)—, phenyl-NRN—C(═O)—, heteroaryl-NRN—C(═O)—, HO—C(═O)—, C1-4-alkyl-O—C(═O)—, —NHRN, C1-4-alkyl-NRN—, C1-4-alkyl-C(═O)NRN—, C3-6-cycloalkyl-C(═O)NRN—, heterocyclyl-O(═O)NRN—, phenyl-O(═O)NRN—, heteroaryl-O(═O)NRN—, C1-4-alkyl-S(═O)2NRN—, C3-6-cycloalkyl-S(═O)2NRN—, heterocyclyl-S(═O)2NRN—, phenyl-S(═O)2NRN—, heteroaryl-S(═O)2NRN—, —OH, C1-4-alkyl-O—, C1-4-alkyl-O—C1-4-alkyl-O—, C3-6-cycloalkyl-O—, heterocyclyl-O—, phenyl-O—, heteroaryl-O—, C1-4-alkyl-S—, C3-6-cycloalkyl-S—, heterocyclyl-S—, phenyl-S—, heteroaryl-S—, C1-4-alkyl-S(═O)—, C3-6-cycloalkyl-S(═O)—, heterocyclyl-S(═O)—, phenyl-S(═O)—, heteroaryl-S(═O)—, C1-4-alkyl-S(═O)2—, C3-6-cycloalkyl-S(═O)2—, heterocyclyl-S(═O)2—, phenyl-S(═O)2—, heteroaryl-S(═O)2—, H2N—S(═O)2—, C1-4-alkyl-NRN—S(═O)2—, heterocyclyl, phenyl, and heteroaryl,
wherein any alkyl, cycloalkyl and heterocyclyl group or sub-group within the groups mentioned is optionally substituted with 1 or more F atoms and optionally substituted with 1 or 2 groups independently selected from H3C—, HO—, H3C—O—, and —CN;
wherein heterocyclyl is selected from
a cyclobutyl group wherein 1 CH2 group is replaced by —NRN— or —O—,
a saturated or partially unsaturated C5-7-cycloalkyl group wherein 1 CH2 group is replaced by —O(═O)—, —NRN—, —O—, —S(═O)— or —S(═O)2— and/or 1 CH group by N;
a saturated or partially unsaturated C5-7-cycloalkyl group wherein 1 CH2 group is replaced by —NRN—, or —O—, a second CH2 group is replaced by —NRN—, —O(═O)—, —S(═O)— or —S(═O)2— and/or 1 CH group is replaced by N; and
a saturated or partially unsaturated C5-7-cycloalkyl group wherein 2 CH2 groups are replaced by —NRN— or 1 CH2 group by —NRN— and the other by —O—, and a third CH2 group is replaced by —O(═O)—, —S(═O)— or —S(═O)2— and/or 1 CH group by N;
and wherein heteroaryl is selected from
a tetrazolyl ring, and a 5- or 6-membered heteroaromatic ring which contains 1, 2, or 3 heteroatoms independently of each other selected from ═N—, —NH—, —O—, and —S—, wherein in heteroaromatic groups containing a —HC═N— unit this group is optionally replaced by —NRN—C(═O)—, and wherein in heteroaromatic rings with one ore more NH groups each of them is replaced by NRN, and
each heteroaryl group is optionally substituted with 1 to 3 substituents independently selected from F, Cl, —CH3, —CN, and —O—CH3;
R6 is selected from the group consisting of F, Cl, Br, I, CN, C1-4-alkyl, C3-6-cycloalkyl-, HO—C1-4-alkyl-, C1-4-alkyl-O—C1-4-alkyl-, RNHN—, C1-4-alkyl-O—, —S(═O)—C1-4-alkyl, and S(═O)2—C1-4-alkyl,
wherein any alkyl and cycloalkyl group or sub-group within the groups mentioned is optionally substituted with one or more F atoms; and
RN is independently of each other selected from the group consisting of H, C1-4-alkyl, C1-4-alkyl-C(═O)—, C1-4-alkyl-NH—C(═O)—, C1-4-alkyl-N(C1-4-alkyl)-C(═O)—, C1-4-alkyl-O—C(═O)—, and C1-4-alkyl-S(═O)2—; and
m is 0, 1, 2, or 3;
wherein in any definition mentioned hereinbefore and if not specified otherwise, any alkyl group or sub-group may be straight-chained or branched,
or a salt thereof.

### Claim 2 (depends on 1)

A compound according to claim 1 with the substructure of formula I.I
wherein R1 is defined as in claim 1,
or a salt thereof.

### Claim 3 (depends on 1, 2)

A compound according to claim 2, wherein
R1 is selected from the group consisting of a phenyl ring, a 5-membered heteroaromatic ring which contains 2 or 3 heteroatoms independently of each other selected from ═N—, —NH—, —O— and —S—, and a 6-membered heteroaromatic ring which contains 1 or 2 ═N— atoms;
wherein in said 5-membered heteroaromatic ring the H-atom in one or more NH groups is replaced with RN or R3, and
wherein each of said phenyl ring, tetrazolyl ring, and heteroaromatic rings is substituted with one group R3 and optionally additionally substituted with 1 or 2 substituents independently selected from R4;
wherein RN, R3 and R4 are defined as in claim 1,
or a salt thereof.

### Claim 4 (depends on 1, 2)

A compound according to claim 2, wherein
R1 is
which is substituted with one group R3 and optionally additionally substituted with 1 or 2 groups independently selected from R4;
wherein R3 and R4 are defined as in claim 1,
or a salt thereof.

### Claim 5 (depends on 1, 2)

A compound according to claim 2 with the substructure of formula I.1
wherein R3 is defined as in claim 1,
or a salt thereof.

### Claim 6 (depends on 2, 3, 4, 5)

A compound according to claims 2 to 5, wherein
R3 is selected from the group consisting of C1-4-alkyl, C1-4-alkyl-O—, and C3-6-cycloalkyl-O—,
wherein each alkyl and cycloalkyl group and each alkyl and cycloalkyl sub-group within the groups mentioned is substituted with 1 to 3 groups independently selected from R5 and optionally substituted with 1 to 3 F atoms;
or from
C3-alkyl-S(═O)2— substituted with 1 HO— or H3C—O— group; and
heterocyclyl-C(═O)—, H2N—C(═O)—, HO—(H3C)2O—CH2—NH—C(═O)—, C1-3-alkyl-NRN—C(═O)—, C1-4-alkyl-C(═O)NRN—, C3-6-cycloalkyl-C(═O)NRN—, heterocyclyl-O(═O)NRN—, C1-4-alkyl-S(═O)2NRN—, heterocyclyl-O—, phenyl-O—, heteroaryl-O—, heterocyclyl-S(═O)2—, heterocyclyl, phenyl, and heteroaryl,
wherein each alkyl, cycloalkyl, and heterocyclyl group or sub-group within the groups mentioned is optionally substituted with 1 or 2 groups independently selected from R5 and optionally substituted with 1 or more F atoms; and
wherein each phenyl and heteroaryl group is optionally substituted with 1 to 3 substituents independently selected from R6;
wherein heterocyclyl is selected from
a cyclobutyl group wherein 1 CH2 group is replaced by —NH— or —O—,
a saturated or mono-unsaturated C5-7-cycloalkyl group wherein 1 CH2 group is replaced by —O(═O)—, —NH—, —O— or —S(═O)2— and/or 1 CH group by N;
a saturated or mono-unsaturated C5-6-cycloalkyl group wherein 1 CH2 group is replaced by —NH— or —O—, a second CH2 group is replaced by —O(═O)— or —S(═O)2— and/or 1 CH group is replaced by N; and
wherein heteroaryl is selected from
tetrazolyl, a 5-membered heteroaromatic ring which contains 1, 2, or 3 heteroatoms independently of each other selected from ═N—, —NH—, O, and S, and a 6-membered heteroaromatic ring which contains 1 or 2 ═N— atoms, wherein a —HC═N— unit is optionally replaced by —NH—C(═O)—;
and wherein in heteroaryl and heterocyclyl rings with one ore more NH groups each of them is replaced by NRN or NR5;
with the proviso that R3 in total cannot be C1-4-alkyl-, C1-4-alkyl-O—C1-4-alkyl, HO—C1-4-alkyl, and C1-4-alkyl-O—;
or a salt thereof.

### Claim 7 (depends on 2, 3, 4, 5)

A compound according to claims 2 to 5, wherein
R3 is selected from the group consisting of C1-4-alkyl, C1-4-alkyl-O—, and C3-6-cycloalkyl-O—,
wherein each alkyl and cycloalkyl group and each alkyl and cycloalkyl sub-group within the groups mentioned is substituted with 1 group selected from R5 and optionally substituted with 1 or 2 H3C— group;
or from
C3-alkyl-S(═O)2— substituted with 1 HO— or H3C—O— group; and
heterocyclyl-C(═O)—, H2N—C(═O)—, HO—(H3C)2C—CH2—NH—C(═O)—, H3C—NRN—C(═O)—, heterocyclyl-O—, heterocyclyl, phenyl, and heteroaryl,
wherein each heterocyclyl group or sub-group within the groups mentioned is optionally substituted with 1 or 2 groups independently selected from R5 and optionally substituted with 1 or more F atoms; and
wherein each phenyl and heteroaryl group is optionally substituted with 1 or 2 substituents independently selected from R6;
wherein heterocyclyl is selected from
a cyclobutyl group wherein 1 CH2 group is replaced by —NH— or —O—;
a saturated or mono-unsaturated C5-7-cycloalkyl group wherein 1 CH2 group is replaced by —O(═O)—, —NH—, —O— or —S(═O)2— and/or 1 CH group by N;
a saturated or mono-unsaturated C5-6-cycloalkyl group wherein 1 CH2 group is replaced by —NH— or —O—, a second CH2 group is replaced by —NH—, —O(═O)— or —S(═O)2— and/or 1 CH group is replaced by N; and
wherein heteroaryl is selected from
tetrazolyl, a 5-membered heteroaromatic ring which contains 1 to 3 heteroatoms independently of each other selected from ═N—, —NH—, —O—, and —S—, and a 6-membered heteroaromatic ring which contains 1 or 2 ═N— atoms, wherein a —HC═N— unit is optionally replaced by —NH—C(═O)—;
wherein in heteroaryl and heterocyclyl rings with one ore more NH groups each of them is replaced by NRN or NR5;
with the proviso that R3 in total cannot be C1-4-alkyl-, C1-4-alkyl-O—C1-4-alkyl, HO—C1-4-alkyl, and C1-4-alkyl-O—;
or a salt thereof.

### Claim 8 (depends on 2, 3, 4, 5)

A compound according to claims 2 to 5, wherein
R3 is selected from the group consisting of
C4-alkyl substituted with 1 HO— and H3C— group;
C2-3-alkyl substituted with 1 group selected from H3C—C(═O)—NH—, H3C—S(═O)2—NH— and H3C—S(═O)2—;
(H3C)3C—CH2—O—;
cyclopropyl-CH2—O— substituted with 1 HO— group;
C1-4-alkyl-O— optionally substituted with 1 or 2 H3C— groups but necessarily substituted with 1 group selected from NC—, H2N—C(═O)—, H3CNH—C(═O)—, (H3C)2N—C(═O)—, (H3C)2N—, H3C—C(═O)—NH—, (H3C)3C—O—C(═O)—NH—, H3C—S(═O)2—NH—, HO—, C1-2-alkyl-O—, H3C—S(═O)—, H3C—S(═O)2—, heterocyclyl, and heteroaryl;
wherein each heterocyclyl group and subgroup is selected from the group consisting of azetidinyl, oxetanyl, pyrrolidin-2-onyl, tetrahydrofuranyl, sulfolanyl, 1,1-dioxo-isothiazolidinyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, and 1,1-dioxo-tetrahydrothiopyranyl, each of which is optionally substituted with 1 group selected from H3C— and HO—, and wherein a NH group, if present, optionally is replaced by C1-3-alkyl-S(═O)2—N; and
wherein heteroaryl is selected from the group consisting of imidazolyl, pyrazolyl, oxazolyl, pyridinyl, and pyridin-2-onyl, wherein a NH group, if present, optionally is replaced by N—CH3 and each heteroaryl is optionally substituted with 1 H3C— or H3C—O— group;
C4-5-cycloalkyl-O— which is substituted with 1 group selected from —N(CH3)S(═O)2CH3 and —OH, and is optionally additionally substituted with 1 H3C— group;
azetidinyloxy, pyrrolidinyloxy, pyrrolidin-2-onyloxy, piperidinyloxy and 1,1-dioxo-[1,2]thiazinanyloxy, in each of which the NH group is optionally replaced by N—CH3 or N—S(═O)2—CH3;
tetrahydrofuranyloxy, tetrahydropyranyloxy, and 1,1-dioxo-tetrahydrothiopyranyloxy;
H2N—C(═O)—, H3C—NH—C(═O)—, HO—(H3C)2C—CH2—NH—C(═O)—, (H3C)2N—C(═O)—, morpholin-4-yl-C(═O)—, tetrahydrofuranyl, 3,6-dihydropyranyl, 1-methanesulfonyl-1,2,3,6-tetrahydropyridinyl, morpholin-4-yl, [1,4]oxazepan-4-yl, 6-oxo-3,6-dihydro-pyran-4-yl;
C3-alkyl-S(═O)2— substituted with 1 HO— or H3C—O— group;
and
phenyl, furanyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyridin-2-onyl, pyrimidin-2-onyl, pyrimidin-4-onyl and pyridazin-3-onyl, wherein a NH group, if present, optionally is replaced by N—CH3, N—CH2—C(CH3)2—OH or N—C(CH3)2—CH2—OH, and which are optionally substituted with 1 H3C— group and optionally substituted with 1 group selected from —CH3, —CH2—CH3, cyclopropyl, —C(CH3)2—OH, and —O—CH3;
or a salt thereof.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A pharmaceutically acceptable salt of a compound according to one or more of the claims 1 to 8.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A pharmaceutical composition comprising one or more compounds according to one or more of the claims 1 to 8 or one or more pharmaceutically acceptable salts thereof, optionally together with one or more inert carriers and/or diluents.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A method for treating diseases or conditions which can be influenced by the modulation of the function of GPR40, particularly, for the prophylaxis and/or therapy of metabolic diseases, such as diabetes, more specifically type 2 diabetes mellitus, and conditions associated with the disease, including insulin resistance, obesity, cardiovascular disease and dyslipidemia in a patient in need thereof, characterized in that a compound according to one or more of the claims 1 to 8 or a pharmaceutically acceptable salt thereof is administered to the patient.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A compound according to one or more of the claims 1 to 8 or a pharmaceutically acceptable salt thereof for use as a medicament.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A compound according to one or more of the claims 1 to 8 or a pharmaceutically acceptable salt thereof for use in the treatment of diseases or conditions which can be influenced by the modulation of the function of GPR40, particularly, for use in the prophylaxis and/or therapy of metabolic diseases, such as diabetes, more specifically type 2 diabetes mellitus, and conditions associated with the disease, including insulin resistance, obesity, cardiovascular disease and dyslipidemia.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A pharmaceutical composition comprising one or more compounds according to one or more of the claims 1 to 8 or one or more pharmaceutically acceptable salts thereof and one or more additional therapeutic agents, optionally together with one or more inert carriers and/or diluents.

### Claim 15 (depends on 14)

A pharmaceutical composition according to claim 14 wherein the additional therapeutic agents are selected from the group consisting of antidiabetic agents, agents for the treatment of overweight and/or obesity and agents for the treatment of high blood pressure, heart failure and/or atherosclerosis
